Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505796-76-00

Acronym

MS202359_0025

Enrollment

Registered

2023-11-27

Start date

2024-01-18

Completion date

2024-08-20

Last updated

2024-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Squamous Cell Carcinoma of the Head and Neck

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026